Rank alternatives on five things: twelve-month spend at the dose you will actually reach, who owns the prescribing relationship, whether the dispensing pharmacy is identified, what happens to money already paid when you stop, and whether an approved brand product is reachable at all. Introductory monthly rates rank last, because every platform discounts month one.
Why the headline rate is the weakest signal
Compounded GLP-1 subscriptions are priced to win a first purchase. MEDVi’s own January 2026 announcement put compounded injections at $179 for the first month with refills at $299, and compounded tablets at $249 to start. That spread is the entire argument: a shopper comparing $179 against a rival’s steady-state figure is comparing a promotion against a price.
The honest unit is a year. Twelve months at a refill rate, plus whatever the platform charges when a prescriber moves someone to a higher strength, plus laboratory work nobody bundles, is the number that separates programs. Treatment in this class is not short. The trial evidence that makes these drugs attractive ran across many months, and the maintenance question is a real one: continued tirzepatide treatment preserved weight reduction in a randomized withdrawal trial, and semaglutide trial participants regained a substantial share of lost weight after stopping.
Who holds the prescribing relationship
Cash-pay telehealth splits into two structures. Some platforms employ or contract clinicians directly. Others route care to an affiliated professional entity, and the marketing brand never touches the prescription. MEDVi is the second kind: its site states that the assessment creates no doctor and patient relationship with MEDVi, that OpenLoop Health clinicians apply the exclusion criteria and retain the decision to prescribe, and that treatment is provided through CareGLP Affiliated P.C.s.
Hims, Ro, Henry Meds, Eden, Mochi Health, Found, and Noom Med all sit somewhere on that spectrum, and several use the same affiliated-entity pattern. It is neither unusual nor improper. It does change who to escalate to when something goes wrong, and it changes what a complaint about the brand can realistically achieve.
The same disclosure varies across the named field, which is why building the shortlist by hand pays off. Hims and Hers, Ro, and Henry Meds each publish compounded GLP-1 terms, HealthRX posts its tirzepatide pricing and refill cadence, and manufacturer routes such as LillyDirect anchor the approved-product end. Lining those up against this program on the five dimensions is more informative than any single headline rate.
Pharmacy identification separates the field faster than price
MEDVi publishes three partner pharmacies in its site footer with addresses and telephone numbers: Triad Rx in Alabama, RedRock Pharmacy in Utah, and Beaker Pharmacy and Compounding in Texas. Several competitors publish nothing equivalent, and one MEDVi-issued press release from January 2026 stated the opposite, that pharmacy names were available on request rather than listed. That inconsistency between a company’s site and its own announcement is itself worth noting when weighing sources.
The reason this matters is documented rather than theoretical. The FDA has reported fraudulent compounded semaglutide and tirzepatide carrying false label information, in some cases naming pharmacies that do not exist and in others naming real pharmacies that did not make the product. A published roster is the only way a patient can check a delivered vial against anything.
What the FDA red flag list adds to a shortlist
The agency publishes a set of telehealth warning signs aimed directly at this market. Among them: claiming a compounded drug is the same as an approved one, discounts that look implausible, medicine that arrives looking different from previous shipments or in damaged packaging without instructions, no screening and prescription by a licensed clinician before medicine ships, no clinician reachable after delivery, and label spelling errors or wrong pharmacy addresses. Running a shortlist against that list eliminates more candidates than any price table.
Rival-published comparisons are useful for structure and worthless for neutrality. The MEDVi breakdown hosted at formblends.com is a fair illustration of both, since it is organized around roughly the right dimensions while being written by a company selling a competing subscription. Take the framework, verify every figure at the source.
| Dimension | Compounded cash subscription | Manufacturer self-pay channel | Insurance route through a clinic |
|---|---|---|---|
| Regulatory status of the drug | Not FDA approved | FDA approved with published labeling | FDA approved with published labeling |
| Typical cash outlay | Lowest, promotional in month one | Mid, published and stable | Copay if covered, full price if not |
| Prescriber | Often an affiliated professional entity | Independent prescriber, pharmacy dispenses | Your own clinician |
| Pharmacy identified | Varies sharply by platform | Yes | Yes |
| Labs and monitoring | Rarely required, rarely bundled | Handled outside the channel | Usually included in care |
| Exit cost | Current cycle typically forfeited | Buy per fill, no subscription | None beyond the visit |
The brand channels belong on the same list
Shoppers often treat approved products as automatically unaffordable and skip them. That is out of date. Eli Lilly sells Zepbound vials directly to self-pay patients and Novo Nordisk sells Wegovy through its own pharmacy channel, both below traditional list pricing, and MEDVi itself offers brand options at a $99 membership plus the medication cost. The gap between a compounded subscription and an approved product has narrowed enough that the comparison should be made rather than assumed.
The tradeoff is straightforward. Approved tirzepatide and semaglutide products carry labeling reviewed for safety, effectiveness, and manufacturing quality. Compounded versions do not, which is most of the reason they cost less. Head-to-head trial data now exists comparing semaglutide and tirzepatide for weight loss, but no trial has studied a compounded preparation, so efficacy expectations for compounded products are inferred from studies of the branded drugs rather than measured.
Frequently asked questions
What single number best predicts the cheaper provider?
Twelve months at the maintenance refill rate, not the introductory rate. Add any strength-based surcharge and a baseline laboratory panel. Programs that look cheapest in month one frequently finish mid-table across a year, and platforms that price by dose climb steadily through the escalation period while flat-rate programs do not.
Is a platform worse because an affiliated entity employs the prescribers?
Not inherently. It is the standard structure across cash-pay telehealth and it is disclosed by most operators. It does determine who is accountable for a clinical decision and who a complaint should be addressed to, so it belongs in the comparison rather than in the fine print.
How much weight should pharmacy disclosure carry?
A lot, relative to how little it costs a company to provide. The FDA has documented compounded GLP-1 products with fabricated or misappropriated pharmacy names on the label. A published roster with addresses gives a patient a way to check what arrived, which no amount of marketing copy substitutes for.
Do compounded and branded tirzepatide perform the same?
No trial has tested that. Randomized evidence for tirzepatide in obesity comes from studies of the approved product, and compounded preparations are assumed to behave similarly because they contain the same active ingredient. The assumption is reasonable and remains untested, which is a meaningful distinction when comparing on value.
Should insurance be checked before choosing a cash platform?
Yes, and most people skip it. Coverage for obesity medication has widened among commercial plans even while Medicare drug coverage has excluded medications used solely for weight loss. A covered approved product beats any cash subscription on both price and regulatory standing when a plan will pay.
